Data as of Sep 18, 2026 · Based on 3,315,446 AI responses across 10,525 prompts · See how Parse measures this
BigHat Biosciencesbighatbio.com · Low evidenceBigHat Biosciences combines a high-speed wet-lab platform with machine learning to enable full-stack antibody discovery and engineering (the Milliner platform). It enables hundreds of recombinant antibodies to be synthesized, purified, and fully characterized for biophysics and function to accelerate development of safer, more effective antibody therapies for challenging diseases. The company pursues strategic pharma collaborations (e.g., Merck, Lilly, Johnson & Johnson) and is advancing programs such as BHB810, a CDH17-directed antibody-drug conjugate in Phase 1 for gastric cancer and other advanced GI tumors, from its San Mateo, CA headquarters.
Parse Score